Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

Completed · Phase 1

Conditions studied: Osteoarthritis

In brief

The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or twice a day for 4 weeks.

Key facts

Study ID

NCT00454298

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

2

Starts

2007-05-01

Expected to finish

2008-03-01

Last updated by the study team

2009-07-29

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Generally healthy, men or women, at least 55 years old
• Osteoarthritis of the knee requiring total knee replacement surgery

You may not qualify if…

• Other types of arthritis, like rheumatoid arthritis
• Recent major surgery (in past 3 months)
• Recent knee injections (in past 6 months)

Where it is running

• Study site — Boston, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Newton, Massachusetts, United States
• Study site — Winchester, Massachusetts, United States
• Study site — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.